Last reviewed · How we verify
AXT-1003
At a glance
| Generic name | AXT-1003 |
|---|---|
| Sponsor | Axter Therapeutics (Beijing) Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of AXT-1003 in Subjects With Advanced Malignant Tumors. (PHASE1)
- Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |